|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.220 SEK | +2.35% |
|
+1.16% | +13.48% |
| 07-24 | Active Biotech Doses First Patient in Amended Ho172 Clinical Study of Tasquinimod in Myelofibrosis | CI |
| 07-24 | Active Biotech Doses First Patient in Amended Tasquinimod Myelofibrosis Trial | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 5.5 | 8.08 | 14.52 |
| Spread/Res. | -5.09% | -35.40% | -64.05% |
| Spread/Supp. | +2.35% | +37.37% | +35.94% |
| Support | 5.1 | 3.8 | 3.84 |
- Stock Market
- Stocks
- ACTI Stock
- ACTI Stock
- Charts Active Biotech AB
Select your edition
All financial news and data tailored to specific country editions
